



ImpediMed Limited  
Suite 31C, 12-18 Tryon Rd  
Lindfield NSW 2070  
Australia

E: [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com)  
W : [impedimed.com](http://impedimed.com)

28 August 2025

Companies Announcements Office  
Australian Securities Exchange

#### **Appendix 4E – Financial year ended 30 June 2025**

ImpediMed Limited (ASX:IPD) provides the attached Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2025.

**Approved for release by the Board of ImpediMed Limited.**

For more information, contact Leanne Ralph, Company Secretary, at  
[leanne.ralph@bellev.com.au](mailto:leanne.ralph@bellev.com.au)

**Appendix 4E**  
**ImpediMed Limited ABN 65 089 705 144**  
**Preliminary Final Report**

- 1 Reporting period:** **Year ended 30 June 2025**  
 Prior Corresponding Reporting Period: Year ended 30 June 2024

**2 Results for announcement to the market**

		% change		\$000
<b>Revenue</b>	up	23%	to	<b>12,724</b>
<b>(Loss) from ordinary activities after tax attributable to members</b>	up	17%	to	<b>-23,237</b>
<b>(Loss) for the period attributable to members</b>	up	17%	to	<b>-23,237</b>
<b>Dividends</b>				
There were no dividends declared and paid during the reporting period on ordinary shares.				
There were no dividends proposed and not yet recognised as a liability during the reporting period.				
<b>Dividend Record Date</b>	<b>Not applicable</b>			
<b>Net tangible assets per security</b>		30-June-2025		30-June-2024
Net tangible assets per security		0.37 cents		1.22 cents

Additional Appendix 4E disclosure requirements are included in the 30 June 2025 Annual Financial Statements lodged with this document. The report is based on the 30 June 2025 Annual Financial Statements which are audited by Ernst & Young and are not subject to dispute, modification, or qualification. The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2025 and any public announcements made by ImpediMed Limited and its controlled entities during the year.